scholarly journals The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma

Blood ◽  
2013 ◽  
Vol 121 (16) ◽  
pp. 3161-3164 ◽  
Author(s):  
Barbara Meissner ◽  
Robert Kridel ◽  
Raymond S. Lim ◽  
Sanja Rogic ◽  
Kane Tse ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Ubiquitin Ligase ◽  
Cell Lymphoma ◽  
E3 Ubiquitin Ligase ◽  
Deleterious Mutations ◽  
Key Points ◽  
Mantle Cell ◽  
Terminal Cluster

Key Points UBR5 is recurrently mutated in mantle cell lymphoma with a C-terminal cluster of deleterious mutations.

scholarly journals Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)

Blood ◽  
2014 ◽  
Vol 123 (11) ◽  
pp. 1665-1673 ◽  
Author(s):  
Julie E. Chang ◽  
Hailun Li ◽  
Mitchell R. Smith ◽  
Randy D. Gascoyne ◽  
Elisabeth M. Paietta ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Eastern Cooperative Oncology Group ◽  
Phase 2 ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Phase 2 Study ◽  
Key Points ◽  
Mantle Cell

Key Points VcR-CVAD produced high overall and CR rates in previously untreated MCL patients. No substantial difference in 3-year PFS or OS was observed in patients receiving ASCT compared with patients receiving maintenance rituximab.

scholarly journals High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma

Blood ◽  
2015 ◽  
Vol 126 (5) ◽  
pp. 604-611 ◽  
Author(s):  
Marie-Hélène Delfau-Larue ◽  
Wolfram Klapper ◽  
Françoise Berger ◽  
Fabrice Jardin ◽  
Josette Briere ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Prognostic Value ◽  
Cell Lymphoma ◽  
Standard Of Care ◽  
High Dose ◽  
Current Standard ◽  
Ki 67 ◽  
Key Points ◽  
Mantle Cell ◽  
High Dose Cytarabine

Key Points CDKN2A and TP53 deletions remain of bad prognostic value in younger MCL patients treated according to the current standard of care. CDKN2A and TP53 deletions have independent deleterious effects and should be considered for treatment decisions in addition to MIPI and Ki-67 index.

scholarly journals TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

Blood ◽  
2017 ◽  
Vol 130 (17) ◽  
pp. 1903-1910 ◽  
Author(s):  
Christian W. Eskelund ◽  
Christina Dahl ◽  
Jakob W. Hansen ◽  
Maj Westman ◽  
Arne Kolstad ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Standard Of Care ◽  
Younger Patients ◽  
Tp53 Mutations ◽  
Key Points ◽  
Mantle Cell ◽  
Frontline Treatment

Key Points The intensified standard-of-care regimens for younger patients with MCL do not overcome the deleterious effects of TP53 mutations. MCLs with TP53 mutations should be considered for alternative frontline treatment.

scholarly journals Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma

2019 ◽  
Vol 3 (20) ◽  
pp. 3132-3135 ◽  
Author(s):  
Manali Kamdar ◽  
Hongli Li ◽  
Robert W. Chen ◽  
Lisa M. Rimsza ◽  
Michael L. Leblanc ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Similar Efficacy ◽  
Key Points ◽  
Mantle Cell

Key Points Five-year follow-up of S1106 demonstrates similar efficacy, MRD negativity, and 5-year survival with RH or RB, but RH was more toxic than RB. RB showed excellent efficacy and survival and less toxicity compared with a cytarabine-based regimen in transplant-eligible MCL patients.

scholarly journals HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma

Blood ◽  
2016 ◽  
Vol 128 (21) ◽  
pp. 2517-2526 ◽  
Author(s):  
Caron Jacobson ◽  
Nadja Kopp ◽  
Jacob V. Layer ◽  
Robert A. Redd ◽  
Sebastian Tschuri ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Hsp90 Inhibitors ◽  
Hsp90 Inhibition ◽  
Key Points ◽  
Mantle Cell ◽  
Ibrutinib Resistance

Key Points Inhibition of HSP90 targets multiple dependences in mantle cell lymphoma. Clinically available HSP90 inhibitors overcome ibrutinib resistance in vitro and in vivo.

scholarly journals Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia

Blood ◽  
2017 ◽  
Vol 130 (6) ◽  
pp. 763-776 ◽  
Author(s):  
Han Zhang ◽  
Zheng Chen ◽  
Roberto N. Miranda ◽  
L. Jeffrey Medeiros ◽  
Nami McCarty
Keyword(s):  
Drug Resistance ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Physiological Conditions ◽  
Key Points ◽  
Mantle Cell

Key Points Downregulation of BACH2 increases MCL proliferation, dispersal, and drug resistance. Distinct crosstalk between BACH2 and HIF-1α under different physiological conditions modifies MCL properties.

scholarly journals Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib

Blood ◽  
2015 ◽  
Vol 126 (13) ◽  
pp. 1565-1574 ◽  
Author(s):  
Baohua Sun ◽  
Bhavin Shah ◽  
Warren Fiskus ◽  
Jun Qi ◽  
Kimal Rajapakshe ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Histone Deacetylases ◽  
Cell Lymphoma ◽  
Synergistic Activity ◽  
Lymphoma Cells ◽  
Key Points ◽  
Mantle Cell ◽  
Bet Protein

Key Points BA reduces MYC, CDK4/6, nuclear RelA, and BTK expression and is synergistically lethal with ibrutinib in MCL cells. Cotreatment with BA and inhibitor of BCL2, CDK4/6, or histone deacetylases is synergistically lethal against ibrutinib-resistant MCL cells.

scholarly journals SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma

Blood ◽  
2014 ◽  
Vol 124 (14) ◽  
pp. 2235-2247 ◽  
Author(s):  
Jara Palomero ◽  
Maria Carmela Vegliante ◽  
Marta Leonor Rodríguez ◽  
Álvaro Eguileor ◽  
Giancarlo Castellano ◽  
...  
Keyword(s):  
Transcriptional Regulation ◽  
Mantle Cell Lymphoma ◽  
Signaling Pathway ◽  
Tumor Angiogenesis ◽  
Cell Lymphoma ◽  
Key Points ◽  
Mantle Cell

Key Points SOX11 mediates regulation of angiogenesis via the PDGFA signaling pathway in MCL. SOX11-dependent increased angiogenesis contributes to a more aggressive MCL phenotype.

scholarly journals Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells

Blood ◽  
2014 ◽  
Vol 123 (6) ◽  
pp. 884-893 ◽  
Author(s):  
Samuel G. Katz ◽  
James L. LaBelle ◽  
Hailong Meng ◽  
Regina P. Valeriano ◽  
Jill K. Fisher ◽  
...  
Keyword(s):  
B Cells ◽  
Transgenic Mice ◽  
Cyclin D1 ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Immune Stimulation ◽  
Key Points ◽  
Mantle Cell ◽  
Stimulation Of

Key Points Immune stimulation of cyclin D1 transgenic mice bearing Bim-deficient B cells induces an MCL phenotype. The induced lymphoma of EμCycD1CD19CREBimfl/fl mice highlights the collaborative roles of Bim deletion and cyclin D1 expression in MCL.

scholarly journals Postibrutinib outcomes in patients with mantle cell lymphoma

Blood ◽  
2016 ◽  
Vol 127 (12) ◽  
pp. 1559-1563 ◽  
Author(s):  
Peter Martin ◽  
Kami Maddocks ◽  
John P. Leonard ◽  
Jia Ruan ◽  
Andre Goy ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Unmet Need ◽  
Poor Outcome ◽  
Key Points ◽  
Mantle Cell

Key Points Patients with mantle cell lymphoma who progressed during treatment with ibrutinib have a poor outcome. There are no therapies that appear to be uniquely successful in the postibrutinib setting. The postibrutinib setting is an unmet need.

Sign in / Sign up

Export Citation Format

Share Document